GlaxoSmithKline divested North American OTC drugs worth about $200 million in sales, a portfolio that seemed like a good strategic fit for buyer Prestige Brands Holdings.
Tysabri gets boost from label change, new diagnostic
Biogen Idec and Elan, which market Tysabri for multiple sclerosis, won approval to add new safety information to the drug’s label that could boost sales by helping doctors avoid a serious adverse event.
New president has ‘big tent’ vision for CME association
Those who produce and fund certified medical education acknowledge that conflict of interest is one issue that seems to constantly crop up. But while conflict is inevitable, bias doesn’t have to be, they insist in a new video.
Privately held inVentiv Health will acquire two of SDI Health’s audit businesses worth under $15 million, according to company statements. IMS Health agreed to divest the units when regulators approved its purchase of SDI last year.
Aiming for more real-world data, AZ cozies up to IMS Health
AstraZeneca has enlisted data supplier IMS Health in an effort to collect evidence on how its treatments are doing outside of controlled clinical trials, firms said.
Two powers of the marketing research arena—Epocrates and M3—partnered today to create what they claim is the world’s largest verified physician and healthcare provider panel.
Small Pharma Marketing Team of the Year: Incivek. From left: Pamela Stephenson, VP of marketing in charge of Incivek brand; Paul Daruwala, VP of marketing/HCV franchise, Vertex Pharmaceuticals